Freemon F R, Al-Marashi M S, Lee J C
J Clin Pharmacol. 1977 Jul;17(7):398-401. doi: 10.1002/j.1552-4604.1977.tb04622.x.
All-night sleep was polygraphically monitored from ten normal volunteers who took placebo and three dosage levels of a new benzodiazepine hypnotic, SCH 16134, in a double-blind, crossover design. All dosages of the drug decreased the time to fall asleep, and the two highest dosages also decreased interspersed wakefulness. REM sleep was suppressed, but slow-wave sleep was not affected in this experiment. The subjective quality of sleep was improved by the new hypnotic. One subject reported that he felt lethargic the day after the largest dose.
对10名服用安慰剂的正常志愿者以及3个剂量水平的新型苯二氮䓬类催眠药SCH 16134,采用双盲交叉设计进行了通宵睡眠的多导睡眠监测。该药物的所有剂量均缩短了入睡时间,两个最高剂量还减少了穿插性觉醒。快速眼动睡眠受到抑制,但在本实验中慢波睡眠未受影响。新型催眠药改善了睡眠的主观质量。一名受试者报告说,服用最大剂量药物后的第二天他感到无精打采。